Achieved by ~ 1 in 3 patients treated over 68 weeks 1 – 3 #
NEW
Start a weight loss transformation 1 – 3 †
†
Mean weight loss of 15 – 17 % ( p < 0.001 vs placebo ) when taken over 68 weeks as an adjunct to a reduced-energy diet and increased physical activity . 1 – 3
≥20 % WEIGHT LOSS
Achieved by ~ 1 in 3 patients treated over 68 weeks 1 – 3 #
#
30.2 % of patients in STEP 1 and 38.6 % of patients in STEP 4 achieved ≥20 % weight loss with Wegovy ® 2.4 mg ; supportive secondary endpoint , p-value not available , not to be used to infer definitive treatment effect . 1 – 3 Mean baseline body weight and BMI across STEP 1 and 4 of 105 – 107 kg and 37.9 – 38.4 kg / m 2 , respectively . 1 – 3 The safety profile of Wegovy ® 2.4 mg was consistent with the GLP-1 RA class . 1 – 3 The most common AEs associated with Wegovy ® 2.4 mg were gastrointestinal ( nausea = 38 %, diarrhoea = 27 %, constipation = 22 %, vomiting = 22 %, abdominal pain = 18 %), headache ( 13 %) and fatigue ( 10 %). 1 Gastrointestinal AEs were predominately of mild-to-moderate severity and subsided over time . 1 – 3 Across four 68-week phase III clinical trials of 2650 adults who received Wegovy ® 2.4 mg , acute pancreatitis was reported in 0.2 % of patients . If suspected , Wegovy ® should be discontinued and only restarted once pancreatitis is ruled out . 1
To learn more about Wegovy ® 2.4 mg , join us online on Thursday 15 August at 8:00 pm AEST for an informative event centred around practical guidance for Wegovy ® 2.4 mg .
This medicinal product is subject to additional monitoring in Australia . This will allow quick identifi cation of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
PBS Information : This product is not listed on the PBS .
Please review full Product Information before prescribing , available at www . novonordisk . com . au / content / dam / nncorp / au / en / pdfs / wegovypi . pdf
Scan QR code to see full Wegovy ® ( semaglutide 2.4 mg ) Product Information
AEs = adverse events ; BMI = body mass index ; GLP-1 RA = glucagon-like peptide-1 receptor agonist . References : 1 . Wegovy ® ( semaglutide 2.4 mg ) Approved Product Information . Available at : www . novonordisk . com . au / content / dam / nncorp / au / en / pdfs / wegovypi . pdf . 2 . Wilding JPH , et al . N Engl J Med . 2021 ; 384:989 – 1002 ( plus supplementary appendix ). 3 . Rubino D , et al . JAMA . 2021 ; 325:1414 – 25 ( plus supplementary appendix ).
Novo Nordisk Pharmaceuticals Pty Ltd . Level 10 , 118 Mount Street , North Sydney NSW 2060 . ABN 40 002 879 996 . Novo Nordisk Medical Information ( Australia ) 1800 668 626 . www . novonordisk . com . au . ® Registered trademark of Novo Nordisk A / S . NOOBOY0034 . AU24SEMO00081 . July 2024 .